Get the Latest Inovio Stock Quote and Company Insights

Inovio's stock quote can be a valuable tool for investors looking to stay up-to-date on the company's performance. You can find the latest Inovio stock quote on financial websites such as Yahoo Finance or Google Finance.

Inovio is a biotechnology company that focuses on developing innovative vaccines and immunotherapies. Its stock is listed on the NASDAQ exchange under the ticker symbol INO.

Investors can track Inovio's stock performance by looking at key metrics such as its market capitalization, which has been steadily increasing over the years. This growth is a testament to the company's potential in the biotech industry.

A different take: New Mountain Finance Corporation Stock

Inovio Pharmaceuticals has reported a significant drop in sales per share over the years, with a value of $0.04 in 2023, down from $6.18 in 2017.

The company's equity ratio has been steadily increasing, reaching 67.85% in 2023, a significant improvement from 3.56% in 2019. This suggests that Inovio has been managing its finances effectively, reducing its debt and increasing its equity.

See what others are reading: Inovio Pharmaceuticals

The debt ratio has been decreasing over the years, with a value of 32.15% in 2023, down from 96.44% in 2019. This indicates that Inovio has been working to reduce its debt burden and become more financially stable.

Here is a summary of Inovio's financial ratios:

Inovio's stock price has been volatile, with a 1-week change of -4.13% and a 1-month change of +14.84%. The current year's performance is +14.21%.

Intriguing read: Twitter Stock Symbol Change

Inovio Pharmaceuticals is expected to see a significant increase in revenue over the next few years, with estimates ranging from $3 million in 2025 to $139 million in 2028.

Their estimated revenue is expected to grow from $3 million in 2025 to $139 million in 2028.

In 2025, Inovio Pharmaceuticals is expected to have a net loss of $111 million, which is expected to decrease to $23 million in 2028.

Their net loss is expected to decrease from $111 million in 2025 to $23 million in 2028.

Research and development expenses are expected to increase from $77 million in 2025 to $96 million in 2028.

Research and development expenses are expected to increase by $19 million from 2025 to 2028.

Selling, general, and administrative expenses are expected to increase from $41 million in 2025 to $56 million in 2028.

Selling, general, and administrative expenses are expected to increase by $15 million from 2025 to 2028.

Their shareholder's equity is expected to be $31 million in 2025.

Their shareholder's equity is expected to be $31 million in 2025.

Here is a summary of the estimated revenue and net income for Inovio Pharmaceuticals:

Estimates can be a crucial aspect of investing in the stock market. Analysts provide earnings estimates, which are predictions of a company's future earnings. For Inovio Pharmaceuticals, the current average estimate for the next year (2026) is -$2.096 USD, based on 4 analysts' predictions.

The number of analysts providing estimates for Inovio Pharmaceuticals has been relatively low in recent quarters. For the current quarter (2025), only 2 analysts provided an estimate, which was -$0.725 USD.

Here's a breakdown of the average estimates for Inovio Pharmaceuticals:

Note that the average estimates have been decreasing over the past few years, with a growth rate estimate of +42.70% from the prior year. This indicates a potential decrease in earnings for the company.

The highest price target for Inovio Pharmaceuticals is $18.00, with an average price target of $10.33. This represents a significant upside of 394.26% to the average price target.

Inovio Pharmaceuticals has a few notable events on their calendar that you should be aware of if you're considering investing in their stock. Specifically, their earnings reports are scheduled for the following dates.

Their Q4 2024 Earnings Release is expected to be -0.837 USD, and it's scheduled for 03/04/2025. This is a crucial date to mark on your calendar if you're interested in tracking their financial performance.

Inovio Pharmaceuticals has a few more earnings reports scheduled for the year. Their Q1 2025 Earnings Release is expected to be -0.725 USD, and it's scheduled for 05/07/2025. This will give you a chance to see how their business is doing after the first quarter of the year.

Here is a summary of their upcoming earnings reports:

Their Q2 2025 Earnings Release is expected to be -0.665 USD, and it's scheduled for 08/07/2025. This will give you a chance to see how their business is doing after the second quarter of the year.

Inovio Pharmaceuticals has one more earnings report scheduled for the year. Their Q3 2025 Earnings Release is expected to be -0.560 USD, and it's scheduled for 11/12/2025.

Inovio Pharmaceuticals has a history of releasing earnings reports, with the most recent one being a Q3 2024 Earnings Release on November 14, 2024, reporting an actual EPS of -0.890 USD.

Their earnings reports have been consistently negative over the past few years, with the lowest EPS being -6.090 USD at the Annual General Meeting on May 21, 2024.

Inovio Pharmaceuticals has also made several announcements in recent months, including a Q3 2024 Earnings Call on November 14, 2024, and a press release announcing the pricing of a $30 million public offering on December 13, 2024.

Their stock price has been affected by various news and announcements, with analysts adjusting their price targets accordingly. For example, Oppenheimer adjusted their price target to $15 from $33, maintaining an Outperform rating, while RBC lowered their price target to $6 from $7, keeping a Sector Perform, Speculative Risk rating.

Here is a list of some of the key events and announcements made by Inovio Pharmaceuticals in recent months:

Their ownership structure is also worth noting, with the majority of shares being held by freefloat (99.18%) and the SPDR S&P Biotech ETF (53.15%).

Inovio is a leader in the field of DNA medicine, with a strong focus on research and development. They have developed a unique platform called DNA medicines, which uses a proprietary electroporation delivery technology to enable the body to produce its own medicine.

Their research and development efforts are driven by a team of experts with a deep understanding of the field. Inovio has a robust pipeline of products in development, including COVID-19 vaccines and immunotherapies for various diseases.

Here's an interesting read: Foundation Medicine

The company has made significant progress in advancing its DNA medicines platform, with several product candidates in various stages of development. Their research and development efforts are focused on leveraging the power of DNA to treat a range of diseases.

Inovio's research and development efforts are guided by a clear vision of using DNA medicines to improve human health. They are committed to delivering innovative solutions to some of the world's most pressing health challenges.

The company's pipeline includes several promising product candidates, including INO-4800, a COVID-19 vaccine candidate that has shown promising results in clinical trials.

A different take: Fundraising for Medical Research